Unknown

Dataset Information

0

JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.


ABSTRACT: Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of CTCL have suggested therapeutic targets, including within the JAK/STAT pathway, but JAK inhibition strategies may be limited by patient-specific mutational status. Because our recent research has highlighted the potential roles of single and combination approaches specifically using BCL2, bromodomain and extra-terminal domain (BET), and histone deacetylase (HDAC) inhibition, we aimed to investigate the effects of JAK inhibition on CTCL cells and established CTCL cell lines when paired with these and other targeting agents. Peripheral blood malignant CTCL isolates exhibited differential responses to JAK inhibition, with JAK2 expression levels negatively correlating to 50% inhibitory concentration (IC50) values. Regardless of single-agent sensitivity, JAK inhibition potentiated malignant cell cytotoxicity in combination with BCL2, BET, HDAC, or proteasome inhibition. Combination inhibition of JAK and BCL2 showed the strongest potentiation of CTCL cytotoxicity, driven by both intrinsic and extrinsic apoptosis pathways. JAK inhibition decreased expression of BCL2 in the high-responder samples, suggesting a putative mechanism for this combination activity. These results indicate that JAK inhibition may have major effects on CTCL cells, and that combination strategies using JAK inhibition may allow for more generalized cytotoxic effects against the malignant cells from patients with CTCL. Such preclinical assessments help inform prioritization for combination targeted drug approaches for clinical utilization in the treatment of CTCL.

SUBMITTER: Yumeen S 

PROVIDER: S-EPMC7252559 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Yumeen Sara S   Mirza Fatima N FN   Lewis Julia M JM   King Amber Loren O ALO   Kim Sa Rang SR   Carlson Kacie R KR   Umlauf Sheila R SR   Surovtseva Yulia V YV   Foss Francine M FM   Girardi Michael M  

Blood advances 20200501 10


Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of CTCL have suggested therapeutic targets, including within the JAK/STAT pathway, but JAK inhibition strategies may be limited by patient-specific mutational status. Because our recent research has highl  ...[more]

Similar Datasets

| S-EPMC6044378 | biostudies-literature
| S-EPMC5768393 | biostudies-literature
| S-EPMC4673282 | biostudies-literature
| S-EPMC6196294 | biostudies-literature
| S-EPMC4826234 | biostudies-literature
| S-EPMC3751846 | biostudies-literature
| S-EPMC5704294 | biostudies-literature
| S-EPMC3357124 | biostudies-literature
| S-EPMC7946638 | biostudies-literature
| S-EPMC6459605 | biostudies-literature